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PTranscatheter Aortic Valve Implantation for
Stenosed and Regurgitant Aortic Valve Bioprostheses
CoreValve for Failed Bioprosthetic Aortic Valve Replacements
Muhammed Z. Khawaja, MBBS,* Peter Haworth, MBBS,* Azad Ghuran, MBCHB, MD,*
Lorraine Lee, BSE,* Adam de Belder, MD,* Neville Hutchinson, MD,* Uday Trivedi, MBBS,*
Jean-Claude Laborde, MD,† David Hildick-Smith, MD*
Brighton, United Kingdom; and Toulouse, France
Transcatheter aortic valve implantation is increasingly being used to treat severe aortic stenosis in patients
with high operative risk. In an aging population the incidence of aortic stenosis is rising, and increasing
numbers of elderly patients are undergoing aortic valve replacement with bioprosthetic valves. Therefore,
there is a corresponding increase in prosthetic degeneration. This presents cardiologists with a cohort of
patients for whom the risk of re-do aortic valve surgery is prohibitive. We present the first series of such
patients with degenerative bioprosthetic stenosis or regurgitation successfully treated with CoreValve
(Medtronic, Luxembourg) implantation. (J Am Coll Cardiol 2010;55:97–101) © 2010 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.060h
w
c
“
p
(
c
fl
i
p
P
n
C
p
F
s
p
d
c
a
m
fi
w
a
p
g
s
a
Pranscatheter aortic valve implantation (TAVI) has entered
he mainstream as a viable treatment option for patients
ith symptomatic, severe aortic stenosis (AS) who are at
rohibitively high surgical risk. The initial success in 2002
1) has been followed by a surge of interest, strengthened by
ncouraging medium-term results with both the self-
xpanding CoreValve (Medtronic, Luxembourg) (2,3) and
alloon-expandable Edwards Sapien (Edwards Lifesciences,
rvine, California) systems (4,5). Although not initially de-
igned for the purpose, the CoreValve (Medtronic) implant is
lso an option for patients with a degenerative aortic valve
ioprosthesis who would be at high surgical risk from repeat
horacotomy. We present a case series of 4 patients in whom
his treatment has been used for failing bioprostheses.
ase Histories
atient #1. A 76-year-old man underwent isolated aortic
alve replacement (AVR) in 1986 for nonrheumatic AS
ith a 23-mm Carpentier-Edwards valve. During 2007 he
ecame increasingly dyspneic and was found to have severe
ortic regurgitation (AR) with moderate AS. His renal
unction was impaired (creatinine 201 mmol/l, estimated
lomerular filtration rate 28 ml/min), and given his resultant
rom the *Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS
rust, Brighton, United Kingdom; and the †Clinique Pasteur, Toulouse, France. Dr.
aborde is a consultant and employee for CoreValve. Dr. Hildick-Smith is a proctor
or CoreValve (Medtronic, Minneapolis, Minnesota).f
Manuscript received May 13, 2009; revised manuscript received June 22, 2009,
ccepted June 29, 2009.igh operative risk score (logistic EuroSCORE 19%), he
as referred for TAVI. Transthoracic echocardiography
onfirmed severe eccentric aortic regurgitation, and the
aortic annulus” measured 21 mm. The procedure was
erformed under conscious sedation as previously described
6). The right radial artery was cannulated, and a 5-F pigtail
atheter was advanced to the aortic root. A 4-F balloon
otation temporary pacing wire was placed via the right
nternal jugular vein. With the left common femoral ap-
roach, the arterial access was prepared for closure with the
rostar (Abbot Vascular Devices, Redwood City, Califor-
ia). The valve was crossed with an Amplatz L1 (Cordis
orp., Miami, Florida) catheter, a hand-curved J-tip Am-
latz SuperStiff guidewire (Boston Scientific Corp., Miami,
lorida) was coiled in the left ventricle, and an 18-F Cook
heath was introduced over the wire. Without valvular
re-dilation, a 26-mm CoreValve (Medtronic) was intro-
uced and positioned under fluoroscopic guidance, with
oncurrent pacing at 150 beats/min to limit the effects of
ortic regurgitation on valve advancement during deploy-
ent. Aortography and hemodynamic monitoring con-
rmed resolution of the aortic regurgitation (Fig. 1). There
as no gradient across the new bioprosthesis on invasive
ssessment. The femoral access site was closed with the
re-laid ProStar suture pair. A post-procedure echocardio-
ram the next day showed normal functioning of the
upra-annular valve, with a peak flow velocity of 2.7 m/s
cross it, and trivial aortic regurgitation.
atient #2. A 66-year-old man underwent AVR in 2001or symptomatic AS with a 21-mm Mitroflow (Sorin Group
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Columbia, Canada) bioprosthe-
sis. Echocardiography revealed
recurrence of aortic stenosis with
regurgitation and significant left
ventricular (LV) dilation. Do-
butamine stress echo revealed an
ejection fraction of 30% with ev-
idence of contractile reserve. The
patient was considered by the
multi-disciplinary team to be at
prohibitively high surgical risk
logistic EuroSCORE 25%) and was accepted for TAVI.
ia the common femoral artery, aortography revealed grade
V AR with a gradient of 100 mm Hg across the valve. A
6-mm CoreValve (Medtronic) device was deployed under
apid ventricular pacing just inferior to the sewing ring of
he original bioprosthesis, with resolution of the AR and a
ransvalvar gradient of 5 mm Hg.
The patient had a diuresis of 4 l over the first 6 h after the
rocedure and immediately felt much better. On the first
ost-operative day, he asked to go home but was persuaded
o stay for an echocardiogram, which showed some early
mprovement in LV function (LV velocity time integral
ising from 17.4 to 18.8 cm).
At 2-month follow-up he was asymptomatic and walking
miles/day. Repeat echocardiography revealed a well-
ositioned implant and improved hemodynamic parameters
ith a peak gradient of 50 mm Hg.
atient #3. An 85-year-old woman was diagnosed with
egeneration of her 18-year-old AVR—a flail leaflet caus-
ng grade IV AR. Due to her high logistic EuroSCORE of
8%, she was referred for TAVI. Via the femoral approach,
26-mm CoreValve (Medtronic) implant was deployed into
he existing xenograft (Fig. 2) as previously described, with
o procedural complications. At 5-month follow-up the
atient reported a vast improvement in her quality of life
ith minimal dyspnea on exertion (New York Heart Asso-
iation [NYHA] functional class I). A transthoracic echo-
Figure 1 Successful Treatment of AR in a Bioprosthetic Aortic
(A) Aortography demonstrating aortic regurgitation (AR) of the bioprosthesis. (B) W
of the CoreValve (Medtronic). (C) Aortography showing the final position of the Cor
Abbreviations
and Acronyms
AR  aortic regurgitation
AS  aortic stenosis
AVR  aortic valve
replacement
LV  left ventricular/
ventricle
TAVI  transcatheter aortic
valve implantationardiogram showed that the CoreValve (Medtronic) was
ell-seated with only a mild paraprosthetic leak and a peak
elocity of 2.4 m/s.
atient #4. This patient underwent implantation of a
5-mm Cryolife-O’Brien (Cryolife International, Atlanta,
eorgia) bioprosthesis in 2002 for AS. At 84 years of age,
he developed degenerative stenosis of her AVR with a
radient of 83 mm Hg and mild AR. Iliac angiography
evealed vessels of insufficient caliber to allow a transfemoral
pproach (Table 1). The multidisciplinary team agreed that
AVI via the left subclavian approach would be her best
ption.
The procedure was performed under general anesthesia.
he left subclavian artery was accessed via a subclavicular
urgical cut-down. Introduction of the 18-F St. Jude (St.
ude Medical, St. Paul, Minnesota) sheath required gradual
otation during advancement, because the fit in the subcla-
ian artery was tight. The marker-tip of the sheath dehisced
uring introduction and was retrieved with an ENSnare
HATCH Medical, L.L.C., Duluth, Georgia) device (Fig. 3).
he 26-mm CoreValve (Medtronic) bioprosthesis was ad-
anced through the tipless sheath and deployed. The skirt
emained constrained, but given the decrease in gradient to
0 mm Hg and complicated procedure, it was accepted
ending further spontaneous valvular expansion.
Later that evening the patient developed a pale, cold, and
ulseless left arm. Emergency subclavian arteriography re-
ealed occlusive subclavian artery dissection. The vessel was
pproached retrogradely via percutaneous brachial artery
ccess. A 7  80 mm LifeStent FlexStar (Edwards Life-
ciences) was implanted, and flow restored. After a stormy
ecovery involving inotropic support and hemofiltration,
epeat echocardiography revealed an increase in transvalvu-
ar gradient to 70 mm Hg. Therefore, we proceeded to
ortic valvuloplasty with a 20-mm BALT (Montmorency,
rance) balloon. This decreased the trans-aortic gradient
rom 70 to 30 mm Hg without demonstrable AR (Figs. 3C
nd 3D). Review at 6 months showed the patient to be well,
YHA functional class II.
Replacement
bioprosthesis as a target for placement
(Medtronic) within the scaffold of the original device without AR.Valve
ith the
eValve
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January 12, 2010:97–101 Transcatheter Aortic Valve Implantation in Failing Aortic BioprosthesesEchocardiography demonstrated good LV function with
peak gradient across the valve of 29 mm Hg and no AR.
iscussion
ur case series demonstrates that the CoreValve (Medtronic)
rosthesis can be safely and effectively deployed in stenotic
nd regurgitant degenerative surgical aortic valve biopros-
heses. Implantation is facilitated by the existing valve
tructure, and immediate results show good hemodynamic
Figure 2 CoreValve Deployment Within a Bioprosthesis
(A) Pre-procedure severe aortic regurgitation (AR). (B) Fully deployed CoreValve (M
atient CharacteristicsTable 1 Patient Characteristics
Patient
#1 #2 #3 #4
Age (yrs) 76 66 85 84
Sex M M F F
NYHA functional class III IV III III
Before procedure
Creatinine (mmol/l) 233 110 100 129
AV peak gradient (mm Hg) 80 100 50 120
LV ejection fraction (%) 60 30 45 65
AR grade 4 4 4 0
MR grade 1 2 2 0
Rhythm AF SR/paced Paced SR
Procedural details
Access gauge 18-F 18-F 18-F 18-F
Pace controlled? Y Y Y Y
Balloon pre-dilation N N N N
Implant size 26 26 26 26
After implant
AR grade 0 0 1 1
AV peak gradient (mm Hg) 39 30 30 35
Post-implant dilation N N N Y
Final AR grade 0 0 1 1
Post-implant PPM? N N/A N/A N
Hospital stay (days) 2 2 6 16
Follow-up (months) 2 3 5 6
AR grade 0 1 1 0
AV peak gradient (mm Hg) 27 58 24 29
F  atrial fibrillation; AR  aortic regurgitation; AV  aortic valve; LV  left ventricular; MR t
itral regurgitation; N/A  not applicable; NYHA  New York Heart Association; PPM 
ermanent pacemaker; SR  sinus rhythm.tatus with a low transvalvular gradient and no AR.
edium- and long-term results are awaited, but in the
eantime, CoreValve (Medtronic) TAVI seems to be an
cceptable alternative to re-do surgery for patients with
egenerative aortic bioprostheses who are at high perioper-
tive surgical risk.
Aortic stenosis remains the most common valvular com-
laint in Europe (7,8), and age is a significant contributing
actor in its natural history (8). The gold standard for
reatment remains surgical AVR (9). The combined effects
f an aging population and the prevalence of AS in this
ohort have led to increasing numbers of elderly patients
eing referred for valvular surgery. The valve of choice in
hese patients is usually a bioprosthetic device, to avoid the
eed for anticoagulation with its associated complications
10). As a result, there is an increasing prevalence of failing
ioprosthetic AVRs. Concurrently, the spectrum of comor-
idities in these patients grows more complex, and therefore
he risks of re-do surgery increase. Absolute surgical risk for
e-do aortic valve operations might be raised by up to 15%
ompared with initial implants (11,12).
The feasibility of implanting a transcatheter valve into a
urgical bioprosthesis was first demonstrated in a pig model
n 2007. The investigators used the Cribier-Edwards system
o transapically implant 23-mm devices into 5 Carpentier
dwards porcine aortic valve prostheses to good effect (13).
case report of successful treatment of a severely regurgitant
ortic valve bioprosthesis with the CoreValve (Medtronic)
ystem has also been described—with retention of good func-
ion and no complications at 1-year follow-up (14).
The risks inherent in the TAVI procedure still exist in
hese patients, as illustrated by the subclavian artery dissec-
ion in Patient #4. However, there are some features that
ake this option attractive. The original bioprosthesis gives
highly visible target for placement of the new implant and
ffers a scaffold that immediately grips the CoreValve
Medtronic) as it is deployed, facilitating accurate place-
ent of the device. Additionally, the uniform circular
ewing ring allows for equal and symmetrical expansion of
ic) prosthesis with (C) almost complete resolution of the AR.edtronhe skirt of the valve such that paraprosthetic AR is unlikely.
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Transcatheter Aortic Valve Implantation in Failing Aortic Bioprostheses January 12, 2010:97–101Several other aspects of this technique warrant discussion in
urther detail. Firstly, in native cases, measurement of the aortic
nnulus is critical to the success of the procedure. In the cases
resented, however, it is simply necessary to know the valvular
iameter of the previously implanted valve. A 26-mm CoreValve
Medtronic) will be the correct option in the vast majority of
ases. It is important to note that internal diameters of 21
m in the aortic valve implant would be insufficient for
oreValve (Medtronic) implantation, exceeding its design
imitations, with a resultant gradient and possible malfunc-
ion of the leaflets resulting in a suboptimal outcome.
Second, although native cases require balloon pre-
ilation under rapid pacing control, this is not necessary
ith re-stenotic valves and indeed is likely to be counter-
roductive for bioprosthetic valves, which might disinte-
rate with risk of stroke or torrential regurgitation. Patients
ith severe aortic regurgitation, however, do benefit from
acing at implant both to reduce systolic pressure and to
educe reflux of blood into the LV, which will augment any
endency for the valve to “move forward” into the ventricle
Figure 3 Retrieval of Fractured Sheath-Tip and Post-Implant Va
(A) The detached sheath tip within the ascending aorta, subsequently secured wit
valvuloplasty with a BALT (Montmorency, France) balloon improving the proximal de
trol). (D) Final position of the CoreValve (Medtronic) device.n deployment. This pacing rate, however, should aim to schieve a systolic blood pressure of 100 mm Hg rather than
he 40 mm Hg used during balloon dilation and can there-
ore persist throughout the valve deployment. Currently,
amponade from temporary pacing wires has ironically
roved one of the most risk-prone aspects of CoreValve
Medtronic) TAVI cases (15), so the lack of need for a
emporary pacing wire in cases without severe AR adds to
he safety of the procedure.
The need for permanent pacing after the procedure is a
imitation of the CoreValve (Medtronic) system. The reg-
stry data suggest a rate of 20% to 25%. In this case series,
one of the patients required a permanent pacemaker,
resumably because the skirt of the valve is primarily
estricted by the sewing ring of the original surgically
mplanted valve, such that compression of the conduction
ystem is much less likely. Waiting to see whether a
acemaker might be required is a drain on bed-days, and it
s advantageous to the patient to be able to mobilize freely
n day 1 without significant risk of heart block.
The technique described in this report makes the use of a
plasty
NSnare (HATCH Medical, L.L.C., Duluth, Georgia) device (B). (C) Post-procedural
ent (note the temporary pacing wire within the right ventricle providing pace con-lvulo
h an E
ploymurgical bioprosthesis rather than a mechanical valve poten-
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January 12, 2010:97–101 Transcatheter Aortic Valve Implantation in Failing Aortic Bioprosthesesially more attractive in patients undergoing conventional
alve replacement (16), and already this trend is being
bserved. However, the resulting internal diameter of the
alve decreases with every deployment. This “Russian doll”
ffect might become more evident in light of successful
rocedures within both bioprosthetic and TAVI replace-
ents and might serve as an additional driver for the
evelopment of valves with smaller diameters. Indeed the
ongest surviving recipient of the CoreValve (Medtronic)
ystem was also the first to have a “valve-in-valve” proce-
ure, and 3-year follow-up has shown maintenance of
linical status and a well-functioning valve (17). It is notable
n our series that the gradients obtained on initial follow-up
re not negligible. Although this is unlikely to be important
n patients for whom there was no other acceptable surgical
lternative, this would not be the case for a patient with a
onger life-expectancy. Similarly, if the valvular gradient
emains stable over time, this is less of a concern than if the
radient begins to rise with ingrowth of tissue.
The evidence for the use of TAVI is limited, as with any
ew technology, and consists of mainly of registry data. This
an often include the steeper initial learning curve—
lthough impressive procedural success rates of 97% and
ortality of 1.5% have recently been reported by a multi-
enter group (18).
onclusions
e have confirmed the viability of TAVI in degenerative
ioprostheses, both stenotic and regurgitant. Long-term
ollow up of these patients is required to demonstrate
ngoing benefits and limitations of this technique.
eprint requests and correspondence: Dr. Muhammed Z. Kha-
aja, Specialist Registrar in Cardiology, Sussex Cardiac Centre,
righton & Sussex University Hospitals NHS Trust, Eastern
oad, Brighton, East Sussex BN2 5BE, United Kingdom. E-mail:
rzeeshan@doctors.org.uk.
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